Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorization of MabThera (rituximab) for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphoc…
-
EMA approval · 2026-08-06EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) by Roche Registration GmbH for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis…
-
EMA approval · 2026-03-20EMA Authorised: Adcetris (Brentuximab vedotin) — Takeda Pharma A/S
EMA authorised Adcetris (brentuximab vedotin) for Hodgkin lymphoma and non-Hodgkin lymphoma, with Takeda Pharma A/S as the marketing authori…
-
FDA approval · 2026-01-16FDA Approved: ZYNLONTA — Supplemental Application (ADC Therapeutics America, Inc.)
The FDA approved a supplemental application for ZYNLONTA (loncastuximab tesirine) filed by ADC Therapeutics America, Inc., effectively updat…
-
EMA approval · 2025-10-06EMA Authorised: Rixathon (rituximab) — Sandoz GmbH
EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-09-29EMA Authorised: Blitzima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorized Blitzima (rituximab) from Celltrion Healthcare Hungary Kft. for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
EMA approval · 2025-09-29EMA Authorised: Truxima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Truxima (rituximab) by Celltrion Healthcare Hungary Kft. as a biosimilar rituximab for several indications including Non-Hodg…
-
EMA approval · 2025-08-05EMA Authorised: Riximyo (rituximab) — Sandoz GmbH
EMA authorized the biosimilar Riximyo (rituximab) by Sandoz GmbH for multiple indications, including Non-Hodgkin lymphoma, rheumatoid arthri…
-
EMA approval · 2025-07-09EMA Authorised: Ituxredi (rituximab) — Reddy Holding GmbH
The EMA authorised Ituxredi (rituximab) by Reddy Holding GmbH. It is indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and r…
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
FDA approval · 2025-06-16FDA Approved: PLERIXAFOR — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved a generic version of plerixafor (Mozobil) for mobilizing hematopoietic stem cells in adults with non-Hodgkin lymphoma or multip…
-
EMA approval · 2025-04-03EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) for multiple indications including Non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphocytic l…
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for a generic version of Plerixafor submitted by Eugia US LLC.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for Plerixafor filed by Novadoz Pharmaceuticals LLC, related to changes to labeling and/or indic…
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.
-
FDA approval · 2024-10-23FDA Approved: JYLAMVO — Supplemental Application (SHORLA ONCOLOGY INC.)
The FDA approved a supplemental application for JYLAMVO (methotrexate) filed by SHORLA ONCOLOGY INC.
-
EMA approval · 2024-10-21EMA Authorised: Zydelig (Idelalisib) — Gilead Sciences Ireland UC
EMA authorised Zydelig (idelalisib) for certain non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
EMA approval · 2024-09-03EMA Authorised: Carmustine medac (previously Carmustine Obvius) (carmustine) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised Carmustine medac (carmustine) for Hodgkin lymphoma and non-Hodgkin lymphoma; the marketing authorization holder is medac Gese…
-
FDA approval · 2024-06-03FDA Approved: METHOTREXATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for methotrexate, authorizing the generic version of the drug.
-
FDA approval · 2024-05-03FDA Approved: PLERIXAFOR — Original Application (Gland Pharma Limited)
FDA approved an original application for a generic version of plerixafor (ANDA206644) from Gland Pharma Limited for stem cell mobilization i…
-
FDA approval · 2024-04-11FDA Approved: PLERIXAFOR — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for plerixafor (generic) under an ANDA. This action approves a change…
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
FDA approval · 2024-02-05FDA Approved: PLERIXAFOR — Supplemental Application (Meitheal Pharmaceuticals Inc.)
The FDA approved a supplemental application for Plerixafor by Meitheal Pharmaceuticals, granting approval for an additional submission relat…